Periodontitis in Patients with Diabetes—
A Complication that Impacts on Metabolic Control

Corneliu Sima, DMD, DSc1 and Michael Glogauer, DDS, PhD2

1. Post-doctoral Fellow and Senior Resident in Periodontology, Faculty of Dentistry;
2. Associate Professor, Faculty of Dentistry and Faculty of Medicine, University of Toronto, Ontario, Canada

Abstract

Diabetes and periodontal diseases (PDs) exhibit a bidirectional relationship centered on an enhanced inflammatory response that manifests both locally and systemically. Diabetes is an established risk factor for PD, whereas the treatment of the latter has been shown to improve glycemic control in diabetic patients. Although compelling evidence from in vitro and animal studies supports a plausible biological explanation for the relationship between the two conditions centered on systemic low-grade inflammation, the limited number of comparable large randomized clinical trials is reflected in the limited specific guidelines offered by the international organizations for diabetes and periodontitis regarding the management of the two diseases in an individual. Further understanding of the biological phenomena underlying PDs and diabetes is critical for individual therapeutic approaches to patients with both conditions by endocrinologists and periodontists.

Keywords
Diabetes, periodontal diseases, inflammation, glycemic control

Disclosure: The authors have no conflicts of interest to declare.

Received: June 5, 2012 Accepted: June 27, 2012 Citation: US Endocrinology, 2012;8(1):35–9 DOI: 10.17925/USE.2012.08.07.35

Diabetes is a multifactorial, life-threatening chronic disease characterized by a dysregulation of the endocrine and metabolic pathways involved in the control of blood glucose levels resulting in hyperglycemia. Uncontrolled diabetes gradually impacts on the nervous and circulatory systems, resulting in irreversible long-term complications. In 2010, approximately 8.3% of the US population—or 25.8 million people—had diabetes either diagnosed (18.8 million) or undiagnosed (7.0 million) and a further 79 million people were estimated to have pre-diabetes according to the Centers for Disease Control and Prevention.1 Chronic hyperglycemia is a hallmark of diabetes regardless of the pathophysiological mechanism of the disease and is regarded as a central player in the development of acute complications—such as hypoglycemic coma, ketoacidotic coma, hyperosmolar non-ketotic coma, myocardial infarction (MI), and stroke—and chronic complications—such as diabetic nephropathy, retinopathy, neuropathy, cardiovascular diseases, peripheral vascular diseases, and periodontal diseases (PDs).

PDs are chronic, microbially induced inflammatory disorders of the tooth-supporting tissues (periodontium) characterized by the progressive destruction of those tissues and ultimately resulting in tooth loss. PDs are the most common inflammatory and bone lytic diseases of humans. Up to 75% of North American adults experience the morbidity and decreased oral function associated with alveolar bone destruction and subsequent edentulism during their lifetime. Oral bone loss takes on additional importance because of recent evidence linking PDs with systemic health conditions including diabetes, cardiovascular disease, and cancer as well as with giving birth to premature children.

Periodontitis, like several other bone diseases (e.g., osteoporosis), is not usually diagnosed until bone loss is well established and damage to skeletal structures has already occurred. Chronic inflammation of gingival tissues called gingivitis represents the initial reversible stage of PD. Although, in some individuals, gingivitis never progresses to PD,3 data suggest that gingivitis always precedes PD and, more importantly, that it represents a clinically relevant risk factor for periodontal attachment loss.4 PD represents the advancement of tissue destruction in the underlying periodontal structures—including the periodontal ligament (PDL), cementum covering the root surfaces, and alveolar bone—compromising tooth stability in the socket (see Figure 1).

In general, three parameters are used to evaluate periodontal status: bleeding on probing (BOP) as indicator of gingivitis, and clinical attachment level (CAL) and alveolar bone loss (ABL) as indices for monitoring PD progression. The quality and quantity of gingival crevicular fluid (GCF), a pseudo-inflammatory exudate found in the gingival crevice, may also be assessed for diagnostic and disease monitoring purposes. Progression of gingivitis to PD is characterized by dysregulated host–biofilm interactions and a failure to resolve local inflammation induced by periodontopathogenic bacteria.
Diabetes and Periodontal Disease

Figure 1: Periodontal Tissues in Health and Disease

In health, periodontal tissues ensure the adequate protection of tooth root surfaces, anchorage and support for the tooth, and absorption and transfer of masticatory forces to the underlying bone. The periodontium is formed of gingival tissues, alveolar bone, PDL (fibers, cells, and extracellular matrix), and cementum covering the root surfaces. The crevice formed between the tooth and gingiva contains an inflammatory exudate that helps protect the junctional epithelium from dental plaque by-products and other irritants. Persistence of dental plaque for up to 21 days and its compositional changes within this interval induce gingivitis, which is characterized by hyperemic tumefaction of free gingiva, an inflammatory PMN infiltrate, and relatively high numbers of T-lymphocytes in the corion. The removal of irritants restores gingival homeostasis, whereas, in susceptible patients, their persistence may lead to periodontal disease (PD). PD is characterized by its compositional changes within this interval induce gingivitis, which is characterized by hyperemic tumefaction of free gingiva, an inflammatory PMN infiltrate, and relatively high numbers of T-lymphocytes in the corion. The removal of irritants restores gingival homeostasis, whereas, in susceptible patients, their persistence may lead to periodontal disease (PD). PD is characterized by irreversible progressive destruction of periodontal structures and a mononuclear cell infiltrate, with B and plasma cells predominating. This results in compromised tooth stability in the socket.

CEJ = cementoenamel junction; PDL = periodontal ligament; PMN = polymorphonuclear neutrophil.

This short article overview the role of diabetes as a risk factor for PD, the impact of PD on diabetic complications and incident diabetes, the effect of periodontal therapy on glycemic control in patients with diabetes, and potential mechanisms linking diabetes and PD.

Diabetes as a Risk Factor for Periodontal Disease

The benefits of glycemic control in patients with diabetes in order to prevent complications have been extensively reported in the literature. The Diabetes control and complications trial (DCCT) and the UK Prospective Diabetes Study (UKDPS), two landmark prospective studies on type 1 and type 2 diabetes, have demonstrated that intensive therapy aimed at blood glucose control reduces the risk of microvascular complications and slows the progression of retinopathy, nephropathy, and neuropathy in diabetic patients. Furthermore, metformin alone significantly reduced the risk of macrovascular disease (myocardial infarction, stroke) and tight blood pressure control significantly reduced the risk of both micro- and macrovascular complications. In addition to these complications, PD had been proposed as a sixth diabetic complication. An association between diabetes and PD has been reported in the literature since the 1960s. The impact of diabetes on periodontal health has been addressed in numerous cross-sectional and longitudinal studies, and diabetes is currently established as a risk factor for PD. Although there is significant heterogeneity between the studies in design and in definition of PD, increasing evidence suggests that poorly controlled diabetes correlates with higher prevalence, severity, and progression rate of PD, compared with controlled diabetes or health. 

Gingivitis is more prevalent in diabetic patients than in healthy individuals regardless of dental plaque index, suggesting an impact of diabetes on local inflammatory response to the bacterial biofilm. In support of this observation, levels of pro-inflammatory cytokines measured in gingival tissues or GCF—in particular interleukin-1 beta (IL-1β)—are increased in patients with poorly controlled diabetes in the absence of PD, compared with non-diabetics and with patients whose diabetes is well controlled. Salvi et al. have reported increasing IL-1β levels in the GCF of patients with or without type 1 diabetes during 21-day experimental gingivitis, with a significant increase in diabetic patients on Day 7 and one week later in healthy individuals. These observations suggest that diabetes favors a gingival pro-inflammatory state prior to onset of PD.

Progression of gingivitis to PD, generally measured by clinical CAL and ABL parameters, also correlates with diabetes and control of the blood glucose (BG). However, the relationship between metabolic control and PD is difficult to define conclusively, since some poorly controlled diabetics do not develop PD and some well controlled diabetics do develop PD. The prevalence of PD is three times higher in poorly controlled diabetics compared with well-controlled diabetics and non-diabetics, according to a large population-based cross-sectional study in the US. Several studies have shown that there is a correlation between glycated hemoglobin (HbA1c) levels and prevalence of PD in diabetic patients, and that CAL is more severe, with more probing depths greater than 3.5 mm, in patients with uncontrolled diabetes. On the contrary, some studies have found little or no correlation between glycemic control and periodontal health—but most of them included younger populations who have a generally lower prevalence of PD. This discrepancy in findings between studies may be due to other metabolic variables not having been taken into account. In fact, one study found a higher correlation between dyslipidemia and PD than between BG control and PD in diabetic patients. Others have...
reported positive correlations between obesity, dyslipidemia, and prevalence and severity of PD in different age groups.\textsuperscript{25–32} Interestingly, in some diabetic patients, subgingival microbiota is predominated by Gram-negative bacteria, particularly rods and fusiforms, partially explaining the higher risk of CAL.\textsuperscript{33–35}

Impact of Periodontal Disease on Diabetic Complications and Incident Diabetes

Two major longitudinal studies with a median follow-up of six and 11 years have linked PD with an increased risk of cardiorenal diabetic complications in patients with type 1 and type 2 diabetes. The first study found a higher incidence of proteinuria and cardiovascular complications—including angina, intermittent claudication, transient ischemic attack, MI, and stroke—in 39 paired Swedish type 1 diabetes patients with severe PD compared with patients with no or mild PD.\textsuperscript{34} The second study looked at 628 Pima Indians with type 2 diabetes and demonstrated a significantly increased adjusted relative risk (3.2, 95 % confidence interval [CI] 1.1–9.3) of cardiorenal mortality in those with severe PD compared with a group who had no, mild, or moderate PD.\textsuperscript{35} Furthermore, PD and edentulism were found to predict incident microalbuminuria and end-stage renal disease in a sample of 529 patients with type 2 diabetes drawn from the same population.\textsuperscript{36} These observations support the earlier one that severe PD in diabetic patients at baseline increases the risk of poor glycemic control at follow-up.

The only two longitudinal studies that investigated the risk of patients with PD developing type 2 diabetes were the first National health and nutrition examination survey (NHANES I) and its follow-up NHEFS (NHANES I epidemiologic follow up study) and a Japanese study, which included 9,296 and 5,848 individuals without diabetes, respectively.\textsuperscript{37,38} While the first study found an adjusted odds ratio of between 1.5 and 2.08 for incident diabetes in patients with high periodontal index scores or tooth loss at baseline, the second study found no association between PD and incident diabetes despite statistically significant positive associations in the unadjusted analyses. However, in both studies, the definition of PD as measure of exposure has been imprecise and thus the interpretation of their results should be made with caution.

Periodontal Therapy and Glycemic Control

Growing evidence suggests that treatment of PD, particularly mechanical root scaling/planning, improves metabolic control in patients with diabetes by significantly reducing HbA\textsubscript{1c} levels,\textsuperscript{40–43} reducing circulating inflammatory mediators (C-reactive protein [CRP], tumor necrosis factor [TNF], IL-6, and fibrinogen) and increasing levels of adiponectin.\textsuperscript{44–47} Two recent systematic reviews\textsuperscript{48,49} overviewed data from eight randomized controlled trials (RCTs)\textsuperscript{20,21,23–25} and two controlled clinical trials (CCTs)\textsuperscript{21–23} of at least three months’ duration that assessed the effects of mechanical periodontal therapy with or without adjunctive antimicrobials on glycemic control in diabetic patients (439 participants in total). The two systematic reviews concluded that the effect of periodontal therapy reduced HbA\textsubscript{1c} levels by a significant 0.40 % (95 % CI -0.77 to -0.04 and -0.78 to -0.01, respectively). The two systematic reviews only had two studies\textsuperscript{21,23} in common, as their inclusion criteria differed slightly; their inclusion criteria were more strict than those of a previous meta-analysis that had found a 0.46 % decrease in HbA\textsubscript{1c} levels following periodontal therapy.\textsuperscript{44} This reduction in HbA\textsubscript{1c} levels may be significant, considering that the UKDPS study demonstrated a 35 % reduction in the risk of cardiovascular complications with each percent reduction in HbA\textsubscript{1c} levels in diabetic patients,\textsuperscript{50} and that a 0.2 % HbA\textsubscript{1c} reduction is associated with a 10 % reduction in mortality in the general population.\textsuperscript{36,51} However, larger RCTs are needed to better understand the impact of PD treatment on glycemic control. Furthermore, the role of adjunctive systemic antibiotics has not yet been fully appreciated.

Potential Mechanisms Linking Periodontal Disease and Diabetes

Several mechanisms by which diabetes influences periodontal tissues have been proposed, including immunological dysfunctions, microvascular changes, and changes in extracellular matrix.\textsuperscript{52,53} Impairment of polymorphonuclear neutrophil adherence, chemotaxis and phagocytosis,\textsuperscript{54,55} and monocyte/macrophage hyper-responsiveness\textsuperscript{56,57} in diabetic patients may explain the higher prevalence and severity of PD in these individuals (see Figure 2). These alterations may result in ectopic inflammatory responses and tissue degradation. Monocyte hyperactivity may be reversed in patients with diabetes by scaling and root planing resulting in reduced monocyte-derived TNF\textsubscript{α}, high-sensitivity CRP, and soluble E-selectin (sE-selectin).\textsuperscript{58} Increased leukocyte adhesion molecule expression and gingival microvascular permeability in diabetes without PD suggests an immune-vascular priming that predisposes to PD.\textsuperscript{59,60} Furthermore, inflammatory-mediated uncoupling of bone formation/resorption is associated with hyperglycemia in the context of reduced osteoblast
pathways in periodontium may explain in part the role of chronic glycation endproducts (AGE) in gingival tissues of diabetic mice has led to the hypothesis that AGE-mediated activation of inflammatory pathways in periodontium may explain in part the role of chronic hyperglycemia in PD. In support of this finding, a cross-sectional study including 69 patients with a mean age of 58 years diagnosed with type 2 diabetes and PD has found a significant association between serum AGE and severity of PD. In addition, advanced glycation of fibronectin and type I collagen significantly impaired human periodontal ligament fibroblasts by reducing their migratory and attaching properties.

PD may impact on glycemic control through transient bacteremia, which could contribute to the initiation and progression of atheroma plaques in arterial walls. This mechanism may involve direct infectious pathogenicity and systemic low-level inflammation that has been correlated with atherosclerosis and cardiovascular diseases. In support of this hypothesis, periodontal pathogens including Porphyromonas gingivalis, Prevotella intermedia, Bacteroides forsythus and Actinobacillus aggregatobacter have been identified in significant quantities in atheromatous plaques, suggesting colonization of emigrated oral bacteria in systemic macrovasculature. Furthermore, the Oral Infections and Vascular Disease Epidemiology study (INVEST) has analyzed 657 dentate subjects with a mean age of 69 years having no history of stroke or MI in order to investigate the relationship between oral microbiota and subclinical atherosclerosis, and found a positive correlation between the four bacterial species and carotid artery intima-media thickness (IMT). The INVEST group has recently reported a direct positive correlation between levels of subgingival bacteria and prevalence of hypertension. Nonetheless, the more frequent detection of P. gingivalis in type 2 diabetes patients with higher HbA1c levels after periodontal therapy indicates that PD may have an impact on BG control in diabetes patients.

Conclusion
PDs are more prevalent and severe in patients with diabetes. Compelling evidence demonstrates that diabetes is a major risk factor for periodontitis regardless of subgingival plaque. Several lines of evidence suggest a potential role of periodontitis in the onset of diabetes and glycemic control through inflammatory and infectious mechanisms. Treatment of periodontitis in diabetic patients results in a modest but significant reduction in HbA1c levels and thus in better glycemcic control. Larger clinical trials are needed to characterize the role of specific periodontal therapies in controlling diabetes.

Diabetes and Periodontal Disease

proliferation, differentiation, and collagen production could be reversed with insulin treatment. One plausible explanation for the link between PD and glycemic control is a low-grade inflammation measured as elevation in systemic pro-inflammatory markers. Mounting evidence suggests that periodontitis in healthy individuals raises the levels of pro-inflammatory and pro-thrombotic mediators in serum and that periodontal therapy is associated with a long-term reduction in pro-inflammatory markers (CRP, TNF-α, and plasminogen activator inhibitor-1) and an improvement of endothelial function (decreased levels of sE-selectin). A dose–response relationship between severity of PD and plasma levels of TNF-α—a cytokine known to promote insulin resistance—was found in adults with type 2 diabetes. The observation of high levels of albumin advanced glycation endproducts (AGE) in gingival tissues of diabetic mice has led to the hypothesis that AGE-mediated activation of inflammatory pathways in periodontium may explain in part the role of chronic hyperglycemia in PD. In support of this finding, a cross-sectional study including 69 patients with a mean age of 58 years diagnosed with type 2 diabetes and PD has found a significant association between serum AGE and severity of PD. In addition, advanced glycation of fibronectin and type I collagen significantly impaired human periodontal ligament fibroblasts by reducing their migratory and attaching properties.

PD may impact on glycemic control through transient bacteremia, which could contribute to the initiation and progression of atheroma plaques in arterial walls. This mechanism may involve direct infectious pathogenicity and systemic low-level inflammation that has been correlated with atherosclerosis and cardiovascular diseases. In support of this hypothesis, periodontal pathogens including Porphyromonas gingivalis, Prevotella intermedia, Bacteroides forsythus and Actinobacillus aggregatobacter have been identified in significant quantities in atheromatous plaques, suggesting colonization of emigrated oral bacteria in systemic macrovasculature. Furthermore, the Oral Infections and Vascular Disease Epidemiology study (INVEST) has analyzed 657 dentate subjects with a mean age of 69 years having no history of stroke or MI in order to investigate the relationship between oral microbiota and subclinical atherosclerosis, and found a positive correlation between the four bacterial species and carotid artery intima-media thickness (IMT). The INVEST group has recently reported a direct positive correlation between levels of subgingival bacteria and prevalence of hypertension. Nonetheless, the more frequent detection of P. gingivalis in type 2 diabetes patients with higher HbA1c levels after periodontal therapy indicates that PD may have an impact on BG control in diabetes patients.

Conclusion
PDs are more prevalent and severe in patients with diabetes. Compelling evidence demonstrates that diabetes is a major risk factor for periodontitis regardless of subgingival plaque. Several lines of evidence suggest a potential role of periodontitis in the onset of diabetes and glycemic control through inflammatory and infectious mechanisms. Treatment of periodontitis in diabetic patients results in a modest but significant reduction in HbA1c levels and thus in better glycemic control. Larger clinical trials are needed to characterize the role of specific periodontal therapies in controlling diabetes.
Periodontitis in Patients with Diabetes—A Complication that Impacts on Metabolic Control

intervention study on glycosylated hemoglobin (HbA1c) and serum, high-sensitivity C-reactive protein (hs-CRP) after local anti-infectious periodontal treatment in type 2 diabetic patients with periodontal disease, Diabetes Res Clin Pract, 2009;83:308-15.


